You are using an older browser version. Please use a supported version for the best MSN experience.

Stocks to buy with Anil Singhvi: Here are Vikas Sethi's top two picks today for good returns

Zee Business logo Zee Business 16-04-2021 zeebizindia@gmail.com (Zee Business)
a screen shot of a person © Provided by Zee Business

Zee Business Managing Editor Anil Singhvi, in the latest episode of ‘Sadabahaar Sethi Saab’ show, spoke to market analyst Vikas Sethi and asked him to reveal his top picks that can generate good returns for investors.

Sethi gave two calls today—one from the cash market and another from F&O space.

See Zee Business Live TV Streaming Below:

About some of his earlier stock picks, Vikas Sethi said that the target on Adani Ports has been achieved today. The buy call on this stock was recommended yesterday.

Cash Market Pick: Hikal is a Buy with Target Price of Rs 190 with stop-loss of Rs 165

Straightaway giving his first pick from the cash market, Vikas Sethi said Hikal Ltd will be his first recommendation of the day. Sethi said that the Pharma sector is seeing good traction today. The first stock that he picked is from the cash segment. Hikal partners with pharmaceuticals, life sciences, biotechnology, agrochemicals, and specialty chemicals companies to deliver active ingredients, intermediates and R&D services.

Sethi said that Hikal has 5 manufacturing plants in Maharashtra and Karnataka. The fundamentals of the company are extremely strong. Return on Capital Employed is 20%, Return on Equity is 14% - 15%, promoters stake is 69%, there is no pledge on this stock and the stock is trading at a P/E multiple of 20. Companies in similar segments are trading at P/E multiples of 35 to 40. The profit for last quarter was extremely strong at Rs 40 cr vs 28 cr (YoY). The target price on the stock is Rs 190 with stop-loss of Rs 165.

F&O Pick: Biocon Futures should be bought with target of Rs 430 and stop-loss of Rs 410

Picking another stock from the Pharma sector in F&O space, Sethi recommended Buy on Biocon Futures. Fundamentals of Biocon are extremely strong. He said that Glenmark has seen good traction after they planned for the IPO of its API segment. Similarly, Biocon’s Subsidiary Biocon Biologics is into the Business of Biosimilars. Biocon is ready with the IPO of its Subsidiary, which will benefit it going forward. This will re-rate Biocon and the stock should be bought with a target of Rs 430 with stop-loss of Rs 410. 

   

More From Zee Business

image beaconimage beaconimage beacon